Yüksel Ürün and Petros Grivas
Aug 23, 2025, 19:39
Yüksel Ürün: Pembrolizumab and Enfortumab Vedotin in Bladder Cancer Treatment
Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared a post on X:
“KEYNOTE905:
Pembrolizumab + Enfortumab Vedotin before and after cystectomy improved EFS, OS and pCR vs surgery alone.
A new SOC may be on the horizon for this high-risk group. Can’t wait to see the full data!”
Petros Grivas, Clinical Director of the GU cancers Program at the University of Washington, shared a post by Yüksel Ürün, adding:
“Agree with Yüksel Ürün this is expected to be paradigm shifting in this population!
Can’t wait to see data! A few questions to ask preemptively:
- % of patients who received adjuvant Nivo in control group
- % histology subtype component
- Subsequent therapies in mUC
- Follow up duration”
More posts featuring Yüksel Ürün on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 23, 2025, 22:57
Aug 23, 2025, 22:35
Aug 23, 2025, 22:10
Aug 23, 2025, 21:42
Aug 23, 2025, 21:31
Aug 23, 2025, 20:55
Aug 23, 2025, 20:22